Since 2019, we have embarked on a translation project to develop a new adjuvant platform for therapeutic cancer and viral vaccines. The adjuvant platform has been filed for patents and this project has gained supports from three technology acceleration agencies. Basically, our invention is a panel of adjuvants that overcome the barrier that current recombinant vaccines encounter, i.e. the failure to induce cytotoxic T lymphocyte immunity which is key to cancer cell killing and eradication of chronic viral infections. The platform consists of three components: 1) the generation of vaccine antigens using eukaryotic, yeast, bacterial and synthesis methods; 2) immunological assays to evaluate responses to vaccines in vivo and ex vivo; and 3) disease models for preclinical efficacy/toxicity studies preparing for clinical trials. A PhD project is available that involves mainly the 1st and 2nd segments.